Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Particular therapeutic challenges are raised by the spondyloarthropathies which represent a key area of unmet medical need. Recent investigations have shown that these conditions are characterised both by altered responsiveness to interleukin(IL)-23 and expansion of IL-23 responsive cells as well as increased production of IL-23. The gut in particular has emerged as a key site of IL-23 production, and gut inflammation is known to be strongly clinically associated with these conditions. Moreover, HLA-B27, which is strongly associated with spondyloarthropathy, has also been shown to stimulate IL-23 production. The view is thus emerging that dysregulation of IL-23 biology is a unifying feature of spondyloarthropathy, suggesting that treatments targeting this cytokine are likely to be highly efficacious.

Original publication

DOI

10.1016/j.coph.2013.03.002

Type

Journal article

Journal

Current opinion in pharmacology

Publication Date

06/2013

Volume

13

Pages

445 - 448

Addresses

University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK. jonsherlock1-bd@yahoo.co.uk

Keywords

Animals, Humans, Spondylarthropathies, Interleukin-23